National Cancer Institute research shows that liquid biopsies (blood tests) can complement current standard-of-care screening. Liquid biopsies hold tremendous potential to transform the diagnosis & treatment paradigm for cancer. But, the first generation of liquid biopsies currently rely on dead cellular material. In contrast, our platform detects material from living cells. We examine the couriers carrying cargo between cells. Cancer cells produce 10x more couriers than normal living cells, making this cancer biomarker easier for early-stage detection before cell death. NurLabs is a patent-pending materials science + bioinformatics approach to detect cancer early when it’s most treatable. We bring a fresh perspective to an old problem.